West Pharma forecasts 2026 profit above estimates on strong demand for drug components

robot
Abstract generation in progress

West Pharmaceutical is forecasting its 2026 annual profit above Wall Street estimates due to high demand for its medical equipment used in diabetes and obesity treatments. Despite concerns about competing oral weight-loss drugs impacting injectables, the company expects continued growth in both formats and projects incremental business from upcoming GLP-1 generics. The company also surpassed fourth-quarter expectations, reporting strong demand for its proprietary products.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский язык
  • Français
  • Deutsch
  • Português (Portugal)
  • ภาษาไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)